Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.
about
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.Tumour biomarkers: homeostasis as a novel prognostic indicatorHuman Genetic Relevance and Potent Antitumor Activity of Heat Shock Protein 90 Inhibition in Canine Lung Adenocarcinoma Cell LinesDefining a standard set of patient-centred outcomes for lung cancer.MiR-661 promotes tumor invasion and metastasis by directly inhibiting RB1 in non small cell lung cancer.RET fusion as a novel driver of medullary thyroid carcinomaTargeting lung cancer through inhibition of checkpoint kinases.Mechanisms of tumor-promoting activities of nicotine in lung cancer: synergistic effects of cell membrane and mitochondrial nicotinic acetylcholine receptors.Biomarkers and targeted systemic therapies in advanced non-small cell lung cancerErbB2-intronic microRNA-4728: a novel tumor suppressor and antagonist of oncogenic MAPK signalingDetection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic featuresPD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survivalHistone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation.Health technology assessment of cancer drugs in Canada, the United Kingdom and Australia: should the United States take notice?The management of brain metastases in non-small cell lung cancer.Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors.Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line.JARID1B modulates lung cancer cell proliferation and invasion by regulating p53 expression.Molecular Profiling of Circulating Tumour Cells Identifies Notch1 as a Principal Regulator in Advanced Non-Small Cell Lung Cancer.Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma.Targeted therapy of brain metastases: latest evidence and clinical implications.Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.Expression of EGFR and molecules downstream to PI3K/Akt, Raf-1-MEK-1-MAP (Erk1/2), and JAK (STAT3) pathways in invasive lung adenocarcinomas resected at a single institution.The alteration of T790M between 19 del and L858R in NSCLC in the course of EGFR-TKIs therapy: a literature-based pooled analysis.
P2860
Q27345462-EA893874-E2D1-4C4E-A164-7056A0A45730Q28069898-4E0BD835-070D-45D3-A80C-A00F248AA6F3Q28550872-01275FD0-F756-45D0-A94D-3C510528BA1CQ30276400-55A7CAC2-0E2A-4CF9-9F65-2C77F15E5B7CQ33913045-5ABB68D9-5DCB-4F56-A085-0E8FAD010147Q35096831-A8C4852D-781E-4447-AAEC-24E6CF580C80Q35128547-3D3EDB4B-CDBC-4B60-B10B-DEEB196065BEQ35204294-7C679315-4888-4F0A-A92B-03E9CCC2082BQ36260477-2E68D4FD-0494-401B-B8E0-4D6913681C67Q36346913-F0DBE72C-FECF-4D1E-AE53-F4A80C185C95Q36444609-4EC4772D-DC80-4C17-BCA6-95936823E0B4Q36545054-2B63670D-C97A-41CD-B9E9-BE65FA174EC9Q37399295-71C0C236-9F55-4723-ACF1-85FE827DF1FAQ38255974-92423B35-0F02-4576-961D-4698246FC167Q38259586-CC88A715-1AE7-420C-9976-F34E47B64C81Q38831440-18DB37A9-FA5B-41E8-ACDC-385A6375795CQ38853393-9B5690BB-3B31-42D5-B111-19C3D328F99AQ38886739-D1128502-0E44-4E5A-BADF-B2687CE8CD61Q42084164-D70645E0-FA22-43E2-A00B-F3352EE7FBD9Q46556584-87F66C27-B18B-440B-AFCE-A553E6122F03Q49956245-2F9A0C75-A1AA-4FD5-9FCD-CE40F5D0F7BCQ51004850-759531FD-0F96-47C1-9409-8E82C7262E70Q51605334-EE111D3B-929F-44E0-A464-8C64D84D3A93Q54388141-30FA8444-B067-450D-9D98-184968DFA965Q54977581-910D1BD2-BEAD-4644-82A6-5AB3F10144F7
P2860
Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Targeted therapies in non-smal ...... dermal growth factor receptor.
@ast
Targeted therapies in non-smal ...... dermal growth factor receptor.
@en
Targeted therapies in non-smal ...... dermal growth factor receptor.
@nl
type
label
Targeted therapies in non-smal ...... dermal growth factor receptor.
@ast
Targeted therapies in non-smal ...... dermal growth factor receptor.
@en
Targeted therapies in non-smal ...... dermal growth factor receptor.
@nl
prefLabel
Targeted therapies in non-smal ...... dermal growth factor receptor.
@ast
Targeted therapies in non-smal ...... dermal growth factor receptor.
@en
Targeted therapies in non-smal ...... dermal growth factor receptor.
@nl
P2860
P1433
P1476
Targeted therapies in non-smal ...... dermal growth factor receptor.
@en
P2093
Eamon M Berge
Robert C Doebele
P2860
P304
P356
10.1053/J.SEMINONCOL.2013.12.006
P577
2013-12-12T00:00:00Z